[Treatment of patients with trophoblastic tumors in the Academic Medical Center: 31 patients in 10 years, 1983-1992]

Ned Tijdschr Geneeskd. 1995 Sep 9;139(36):1829-34.
[Article in Dutch]

Abstract

Objective: Evaluation of the treatment of patients with gestational trophoblastic disease.

Setting: Academic Medical Centre, Amsterdam.

Design: Descriptive.

Method: Clinical data from all patients treated between 1983 and 1992 were collected.

Results: Thirty-one patients were treated in this period. Eighteen patients had persistent trophoblast after a molar pregnancy, 7 had choriocarcinoma after a normal pregnancy and in 6 patients the obstetrical history was unclear. The initial treatment strategy was chosen on the basis of prognostic factors; low-risk patients received mono-chemotherapy (Methotrexate) and high-risk patients were treated with polychemotherapy (EMA/CO). In 15 cases adjuvant therapy was necessary. Complete remission was achieved in 29 patients, 2 patients died. The adverse effects of the chemotherapy were generally mild.

Conclusion: Persistent trophoblastic disease has an unpredictable presentation and course. Therefore treatment should preferably be given in a reference centre.

Publication types

  • English Abstract

MeSH terms

  • Adult
  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
  • Choriocarcinoma / drug therapy
  • Choriocarcinoma / pathology
  • Combined Modality Therapy
  • Cyclophosphamide / administration & dosage
  • Dactinomycin / administration & dosage
  • Etoposide / administration & dosage
  • Female
  • Humans
  • Hydatidiform Mole / pathology
  • Methotrexate / administration & dosage
  • Methotrexate / therapeutic use*
  • Pregnancy
  • Prognosis
  • Retrospective Studies
  • Trophoblastic Neoplasms / drug therapy*
  • Trophoblastic Neoplasms / surgery
  • Uterine Neoplasms / drug therapy*
  • Uterine Neoplasms / surgery
  • Vincristine / administration & dosage

Substances

  • Dactinomycin
  • Vincristine
  • Etoposide
  • Cyclophosphamide
  • Methotrexate

Supplementary concepts

  • EMA-CO protocol